|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Biochemistry and
2 Howard Hughes Medical Institute, Biomolecular Structure Center, University of Washington, Seattle, Washington 98195, USA
3 Department of Chemistry and Ohio State Biochemistry Program, The Ohio State University, Columbus, Ohio 43210, USA
(RECEIVED September 24, 2003; FINAL REVISION November 6, 2003; ACCEPTED November 7, 2003)
Keywords: crystal engineering; drug design; malaria; PDF; Plasmodium
Reprint requests to: Wim G.J. Hol, Box 357742, University of Washington, Seattle, Washington 98195, USA; e-mail: wghol{at}u.washington.edu; fax: (206) 685-7002.
Article published online ahead of print. Article and publication date are at http://www.proteinscience.org/cgi/doi/10.1110/ps.03456404.
4 Present addresses: Plexxikon, Inc., Berkeley, CA 94710, USA;
5 Amersham Biosciences, Fast Trak, Uppsala, Sweden 751 84.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Fieulaine, C. Juillan-Binard, A. Serero, F. Dardel, C. Giglione, T. Meinnel, and J.-L. Ferrer The Crystal Structure of Mitochondrial (Type 1A) Peptide Deformylase Provides Clear Guidelines for the Design of Inhibitors Specific for the Bacterial Forms J. Biol. Chem., December 23, 2005; 280(51): 42315 - 42324. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |